CENICRIVIROC COMBINATION THERAPY FOR THE TREATMENT OF FIBROSIS

• 收藏
• 分享

专利权人:

Inc.;Tobira Therapeutics

发明人:

Eric LEFEBVRE

申请号：

US15759886

公开号：

US20180360846A1

申请日:

2016.03.16

申请国别(地区):

US

年份:

2018

代理人:

摘要：

Cenicriviroc (CVC) is an orally active antagonist of ligand binding to C—C chemokine receptor type 5 (CCR5) and C—C chemokine receptor type 2 (CCR2). CVC blocks the binding of RANTES, MIP-1α, and MIP-1β to CCR5, and of MCP-1/CCL2 to CCR2. Methods of treating fibrosis and related conditions comprising co-administration of CVC with chemokine antagonists, FXR agonists, high dose vitamin E (>；400 iU/d), a peroxisome proliferator-activated receptor alpha (PPAR-α) agonist, PPAR-γ agonist, and/or PPAR-δ agonist are provided herein.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/